Emergent BioSolutions’ (EBS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Emergent BioSolutions (NYSE:EBS) in a research report released on Friday morning,Benzinga reports. The firm currently has a $15.00 target price on the biopharmaceutical company’s stock.

Separately, StockNews.com lowered Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th.

Emergent BioSolutions Price Performance

Shares of Emergent BioSolutions stock opened at $5.70 on Friday. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The firm has a market capitalization of $309.45 million, a PE ratio of -1.39 and a beta of 1.80. The business’s 50-day moving average price is $8.48 and its 200-day moving average price is $8.71. Emergent BioSolutions has a 12 month low of $1.82 and a 12 month high of $15.10.

Emergent BioSolutions (NYSE:EBS) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.40. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The business had revenue of $194.70 million for the quarter, compared to analyst estimates of $254.67 million. During the same period last year, the company earned ($0.77) EPS. Sell-side analysts forecast that Emergent BioSolutions will post -0.63 EPS for the current fiscal year.

Insider Transactions at Emergent BioSolutions

In other news, Director Neal Franklin Fowler sold 35,000 shares of Emergent BioSolutions stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the sale, the director now directly owns 101,100 shares in the company, valued at approximately $589,413. This trade represents a 25.72 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Emergent BioSolutions

A number of large investors have recently made changes to their positions in EBS. State Street Corp grew its position in shares of Emergent BioSolutions by 864.7% in the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock worth $15,960,000 after buying an additional 1,713,200 shares during the last quarter. Oak Hill Advisors LP purchased a new position in shares of Emergent BioSolutions in the 3rd quarter valued at approximately $9,296,000. Millennium Management LLC lifted its stake in shares of Emergent BioSolutions by 83.0% in the 4th quarter. Millennium Management LLC now owns 1,481,906 shares of the biopharmaceutical company’s stock valued at $14,167,000 after purchasing an additional 671,947 shares during the period. Invesco Ltd. lifted its stake in shares of Emergent BioSolutions by 70.9% in the 4th quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company’s stock valued at $14,722,000 after purchasing an additional 638,995 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Emergent BioSolutions by 67.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company’s stock valued at $10,554,000 after purchasing an additional 444,790 shares during the period. 78.40% of the stock is currently owned by institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.